Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT05422963
  4. Details
NCT05422963 Clinical Trial

Multiple-Center Retrospective Study of Severe and Critical COVID-19 in Shanghai

COVID-19 Clinical Trial

Official title:
Multiple-Center Retrospective Study of Severe and Critical COVID-19 in Shanghai

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT05422963
Other study ID # SCCS-2022-1
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date June 10, 2022
Est. completion date June 10, 2023

Study information
Verified date June 2022
Source Ruijin Hospital
Contact Ying Chen, PhD
Phone +8613917403314
Email cy11530@rjh.com.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is to clarify the clinical characteristics of severe and critical COVID-19 from March 1st ,2022 to June 9th, 2022 in Shanghai and to explore the relationship between the characteristics and prognosis in these patients.

Description:

1. To Describe the clinical characteristics of severe and critical COVID-19. 2. To analyze the relationship between the clinical characteristics and their clinical prognosis; 3. To analyze the relationship between clinical intervention and their clinical prognosis.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 1000
Est. completion date June 10, 2023
Est. primary completion date June 10, 2023
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - severe and critical covid-19 patients who met the "Diagnosis and Treatment Plan for new Coronavirus Pneumonia (Ninth Edition)" - admission time more than 24 hours Exclusion Criteria: - admission time less than 24 hours

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
China Ruijin Hospital Shanghai

Sponsors (1)
Lead Sponsor Collaborator
Ruijin Hospital

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary 28-day mortality 28-day mortality of severe and critical COVID-19 one year
Secondary 60-day mortality 60-day mortality of severe and critical COVID-19 one year
Secondary ICU length of stay ICU length of stay one year
Secondary the percentage of organ failure the percentage of organ failure include respiratory,circulatory failure and so on one year
Secondary time for virus to turn negative time for COVID-19 from positive to negative one year
Secondary The overall description The overall description of the clinical characteristics in severe and critical covid-19 one year
See also
  Status Clinical Trial Phase
Recruiting NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Active, not recruiting NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure